The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5

被引:99
|
作者
Zwick, MB
Komori, HK
Stanfield, RL
Church, S
Wang, M
Parren, PWHI
Kunert, R
Katinger, H
Wilson, IA
Burton, DR
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[4] Univ Nat Resources, Inst Appl Microbiol, Vienna, Austria
关键词
D O I
10.1128/JVI.78.6.3155-3161.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human monoclonal antibody 2F5 neutralizes primary human immunodeficiency virus type 1 (HfV-1) with rare breadth and potency. A crystal structure of a complex of 2F5 and a peptide corresponding to its core epitope on gp41, ELDKWAS, revealed that the peptide interacts with residues at the base of the unusually long (22-residue) third complementarity-determining region of the heavy chain (CDR H3) but not the apex. Here, we perform alanine-scanning mutagenesis across CDR H3 and make additional substitutions of selected residues to map the paratope of Fab 2F5. Substitution of residues from the base of the H3 loop or from CDRs H1, H2, and L3, which are proximal to the peptide, significantly diminished the affinity of Fab 2F5 for gp41 and a short peptide containing the 2F5 core motif. However, nonconservative substitutions to a phenylalanine residue at the apex of the H3 loop also markedly decreased 2F5 binding to both gp41 and the peptide, suggesting that recognition of the core epitope is crucially dependent on features at the apex of the H3 loop. Furthermore, substitution at the apex of the H3 loop had an even more pronounced effect on the neutralizing activity of 2F5 against three sensitive HIV-1. These observations present a challenge to vaccine strategies based on peptide mimics of the linear epitope.
引用
收藏
页码:3155 / 3161
页数:7
相关论文
共 50 条
  • [31] Structure-based discovery of small molecules improving stability of human broadly-neutralizing anti-HIV antibody 2F5 in plant suspension cells
    Mandal, Manoj K.
    Kronenberger, Thales
    Zulka, Marie, I
    Windshugel, Bjorn
    Schiermeyer, Andreas
    BIOTECHNOLOGY JOURNAL, 2022, 17 (04)
  • [32] An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
    Nelson, Josh D.
    Brunel, Florence M.
    Jensen, Richard
    Crooks, Emma T.
    Cardoso, Rosa M. F.
    Wang, Meng
    Hessell, Ann
    Wilson, Ian A.
    Binley, James M.
    Dawson, Philip E.
    Burton, Dennis R.
    Zwick, Michael B.
    JOURNAL OF VIROLOGY, 2007, 81 (08) : 4033 - 4043
  • [33] A BROADLY NEUTRALIZING MONOCLONAL-ANTIBODY THAT RECOGNIZES THE V3 REGION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GLYCOPROTEIN GP120
    OHNO, T
    TERADA, M
    YONEDA, Y
    SHEA, KW
    CHAMBERS, RF
    STROKA, DM
    NAKAMURA, M
    KUFE, DW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) : 10726 - 10729
  • [34] Interaction of Anti-HIV Type 1 Antibody 2F5 with Phospholipid Bilayers and Its Relevance for the Mechanism of Virus Neutralization
    Maeso, Ruben
    Huarte, Nerea
    Julien, Jean-Philippe
    Kunert, Renate
    Pai, Emil F.
    Nieva, Jose L.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (08) : 863 - 876
  • [35] Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection
    Bunnik, Evelien M.
    van Gils, Marit J.
    Lobbrecht, Marilie S. D.
    Pisas, Linaida
    van Nuenen, Ad C.
    Schuitemaker, Hanneke
    VIROLOGY, 2009, 390 (02) : 348 - 355
  • [36] Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120
    Wilkinson, RA
    Piscitelli, C
    Teintze, M
    Cavacini, LA
    Posner, MR
    Lawrence, CM
    JOURNAL OF VIROLOGY, 2005, 79 (20) : 13060 - 13069
  • [37] 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d][1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity
    Di Santo, R
    Costi, R
    Artico, M
    Massa, S
    Marongiu, ME
    Loi, AG
    De Montis, A
    La Colla, P
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (02): : 127 - 137
  • [39] Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1
    Zwick, MB
    Jensen, R
    Church, S
    Wang, M
    Stiegler, G
    Kunert, R
    Katinger, H
    Burton, DR
    JOURNAL OF VIROLOGY, 2005, 79 (02) : 1252 - 1261
  • [40] COMPARISON OF THE MOUSE ANTIBODY-RESPONSE TO DIFFERENT ANTIGENIC FORMULATIONS INCORPORATING A SYNTHETIC PEPTIDE REPRESENTING THE HEAVY-CHAIN 2ND COMPLEMENTARITY-DETERMINING REGION OF A MOUSE MONOCLONAL ANTI-CD4 ANTIBODY
    KANDA, P
    FRITZ, DA
    DUNHAM, RG
    SHULER, KR
    LOHMAN, KL
    KENNEDY, RC
    BUCK, D
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (08) : 1385 - 1385